trifluridine has been researched along with Esophageal Squamous Cell Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, H; Hironaka, S; Horimatsu, T; Ishihara, R; Kasai, H; Kato, K; Kawaguchi, A; Kikuchi, O; Kojima, T; Mori, Y; Mukai, K; Muto, M; Tada, H; Tsushima, T; Uozumi, R | 1 |
1 trial(s) available for trifluridine and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoplasm Recurrence, Local; Platinum Compounds; Pyrrolidines; Taxoids; Trifluridine | 2022 |